MORF
|Morphic Holding Inc
NASDAQ
USD
|%
Current Price
Change
(%)
P/E Ratio
Dividend Yield
Market Cap
2.86B
Volume
Open
Previous Close
52-Week High
USD 57.00
52-Week Low
USD 25.25
About Morphic Holding Inc
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indicat...
Sector:Healthcare
Industry:Biotechnology
CEO:Dr. Praveen P. Tipirneni M.B.A., M.D.
Employees:128
Headquarters:Waltham, USA
Website:www.morphictx.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions